Richard C OBrien
Overview
Explore the profile of Richard C OBrien including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
95
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Page M, Hardikar W, Alex G, Bates S, Srinivasan S, Stormon M, et al.
Atherosclerosis
. 2023 Oct;
387:117305.
PMID: 37863699
Background And Aims: Homozygous familial hypercholesterolaemia (FH) causes severe cardiovascular disease from childhood. Conventional drug therapy is usually ineffective; lipoprotein apheresis (LA) is often required. Liver transplantation (LT) can correct...
2.
Tada H, Yeo K, Li J, Tan K, Ako J, Krittayaphong R, et al.
JACC Asia
. 2022 Nov;
1(3):294-302.
PMID: 36341217
Approximately one-half of the phenotypic susceptibility to atherosclerotic cardiovascular disease (ASCVD) has a genetic basis. Although individual allelic variants generally impart a small effect on risk for ASCVD, an emerging...
3.
Eer A, Hearn T, Atkinson-Briggs S, Drake S, Singh S, Neoh S, et al.
Intern Med J
. 2022 Jun;
53(5):787-797.
PMID: 35717668
Background: Aboriginal and Torres Strait Islander people have higher rates of diabetes and its complications than non-Aboriginal people. Rumbalara Aboriginal Co-operative is the major primary healthcare provider for Aboriginal people...
4.
Li J, Yeo K, Tan K, Ako J, Krittayaphong R, Tan R, et al.
Am J Prev Cardiol
. 2021 Jul;
4:100096.
PMID: 34327472
With the global spread of abdominal obesity, cardiovascular disease continues to spread to all countries of the world. Given the large population, the challenges presented by cardiometabolic risk in the...
5.
Page M, Ekinci E, Burnett J, Hooper A, Reid N, Bishop W, et al.
J Clin Apher
. 2020 Sep;
36(1):48-58.
PMID: 32911577
Introduction: Severe familial hypercholesterolaemia (FH) causes premature disability and death due to atherosclerotic cardiovascular disease and is refractory to standard lipid-lowering therapies. Lipoprotein apheresis (LA) has long been a standard...
6.
Pang J, Sullivan D, Hare D, Colquhoun D, Bates T, Ryan J, et al.
Heart Lung Circ
. 2020 Sep;
30(3):372-379.
PMID: 32873489
Background: Familial hypercholesterolaemia (FH) is under-diagnosed and under-treated worldwide, including Australia. National registries play a key role in identifying patients with FH, understanding gaps in care and advancing the science...
7.
Li J, Liu H, Wu N, Yeo K, Tan K, Ako J, et al.
Expert Opin Drug Metab Toxicol
. 2020 Jul;
16(9):837-851.
PMID: 32729743
Introduction: Statins have been established as the standard of care for dyslipidemia and preventing cardiovascular diseases while posing few safety concerns. However, misconceptions about statin intolerance lead to their underuse,...
8.
Oo H, Giovannucci J, OBrien R, Hare D
Heart Lung Circ
. 2020 Apr;
29(11):1682-1687.
PMID: 32299761
Background: Elevated lipoprotein(a) (Lp(a)) is an inherited lipid disorder and an independent risk factor for cardiovascular (CV) disease. Although its prevalence in the general population has been well-documented, the prevalence...
9.
Bellgard M, Walker C, Napier K, Lamont L, Hunter A, Render L, et al.
J Atheroscler Thromb
. 2017 Mar;
24(10):1075-1084.
PMID: 28344196
Familial Hypercholesterolemia (FH) is the most common and serious monogenic disorder of lipoprotein metabolism that leads to premature coronary heart disease. There are over 65,000 people estimated to have FH...
10.
Ryan A, Goss B, Waring J, OBrien R
Med Teach
. 2014 Apr;
36(6):546.
PMID: 24754340
No abstract available.